Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder

Lenard A Adler, David Goodman, Richard Weisler, Mohamed Hamdani, Thomas Roth, Lenard A Adler, David Goodman, Richard Weisler, Mohamed Hamdani, Thomas Roth

Abstract

Background: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This analysis aimed to evaluate the impact of lisdexamfetamine dimesylate (LDX) on sleep quality in adults with ADHD.

Methods: This 4-week, phase 3, double-blind, forced-dose escalation study of adults aged 18 to 55 years with ADHD randomized participants to receive placebo (n = 62), or 30 (n = 119), 50 (n = 117), or 70 (n = 122) mg/d LDX, taken once a day in the morning. The self-rated Pittsburgh Sleep Quality Index (PSQI) was administered at baseline and at week 4 to assess sleep quality. The PSQI global score assesses 7 sleep components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction) each scored from 0 (no difficulty) to 3 (severe difficulty).

Results: The mean baseline PSQI global score was 5.8 for LDX and 6.3 for placebo (P = .19) indicating poor overall sleep quality. At endpoint, least squares (LS) mean change from baseline was -0.8 for LDX vs -0.5 for placebo (P = .33). The daytime functioning component showed significant improvement in LS mean change at endpoint for LDX compared with placebo (LDX -0.4 vs placebo 0.0, P = .0001). LS mean changes for the other 6 PSQI components did not significantly differ from placebo. Sleep-related treatment-emergent adverse events with an incidence >/=2% in the active treatment and placebo groups, respectively, were insomnia (19.3% and 4.8%), initial insomnia (5.0% and 3.2%), middle insomnia (3.6% and 0%), sleep disorder (0.6% and 3.2%), somnolence (0.3% and 3.2%), and fatigue (4.7% and 4.8%), and were generally mild or moderate in severity.

Conclusion: For most subjects, LDX was not associated with an overall worsening of sleep quality and significantly improved daytime functioning in adults with ADHD.

Trial registration: clinicaltrials.gov Identifier: NCT00334880.

Figures

Figure 1
Figure 1
Subject disposition. (LDX = lisdexamfetamine dimesylate; AEs = adverse events).
Figure 2
Figure 2
Effect of LDX on global PSQI scores. Mean global PSQI scores of all treatment groups decreased from baseline indicating an improvement in sleep quality. Numbers within bars indicate numbers of subjects. (SD = standard deviation; SE = standard error; LS = least squares; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate).
Figure 3
Figure 3
Effect of LDX on daytime dysfunction (component 7) PSQI scores. Mean PSQI component 7 score (daytime dysfunction component) decreased significantly after treatment with LDX. Numbers within bars indicate numbers of subjects. (SD = standard deviation; SE = standard error; LS = least squares; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate). P-values for "all LDX doses" calculated by analysis of covariance with baseline score as covariate. P-values for individual LDX dose groups calculated by Dunnett's test for multiple mean comparisons with least-squares (LS) adjustment. * P < .01 vs placebo.
Figure 4
Figure 4
PSQI global scores for subjects reporting sleep-related TEAEs. PSQI scores are not worse at 4 weeks for subjects who reported sleep-related TEAEs. Numbers within bars indicate numbers of subjects. (TEAEs = treatment-emergent adverse events; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate; SD = standard deviation).

References

    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders Text Revision. Fourth. Washington, DC: American Psychiatric Association; 2000. Attention-deficit and disruptive behavior disorders.
    1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237–248. doi: 10.1016/S0140-6736(05)66915-2.
    1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948. doi: 10.1176/appi.ajp.164.6.942.
    1. Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65:1301–1313.
    1. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546–557. doi: 10.1097/00004583-199007000-00007.
    1. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111:279–289. doi: 10.1037/0021-843X.111.2.279.
    1. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–723. doi: 10.1176/appi.ajp.163.4.716.
    1. Philipsen A, Hornyak M, Riemann D. Sleep and sleep disorders in adults with attention deficit/hyperactivity disorder. Sleep Med Rev. 2006;10:399–405. doi: 10.1016/j.smrv.2006.05.002.
    1. Mick E, Biederman J, Jetton J, Faraone SV. Sleep disturbances associated with attention deficit hyperactivity disorder: the impact of psychiatric comorbidity and pharmacotherapy. J Child Adolesc Psychopharmacol. 2000;10:223–231. doi: 10.1089/10445460050167331.
    1. Owens JA. The ADHD and sleep conundrum: a review. J Dev Behav Pediatr. 2005;26:312–322. doi: 10.1097/00004703-200508000-00011.
    1. Kass SJ, Wallace JC, Vodanovich SJ. Boredom proneness and sleep disorders as predictors of adult attention deficit scores. J Atten Disord. 2003;7:83–91. doi: 10.1177/108705470300700202.
    1. Adler LA, Reingold LS, Morrill MS, Wilens TE. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–415. doi: 10.1007/s11920-006-0044-9.
    1. Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:233–260. doi: 10.1016/S0193-953X(03)00091-1.
    1. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524–540.
    1. Zhang L, Samet J, Caffo B, Punjabi NM. Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol. 2006;164:529–537. doi: 10.1093/aje/kwj231.
    1. Broderick P, Benjamin AB. Caffeine and psychiatric symptoms: a review. J Okla State Med Assoc. 2004;97:538–542.
    1. Dalby JT. Will population decreases in caffeine consumption unveil attention deficit disorders in adults? Med Hypotheses. 1985;18:163–167. doi: 10.1016/0306-9877(85)90049-0.
    1. Altfas JR. Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment. BMC Psychiatry. 2002;2:9. doi: 10.1186/1471-244X-2-9.
    1. Wolk R, Somers VK. Sleep and the metabolic syndrome. Exp Physiol. 2007;92:67–78. doi: 10.1113/expphysiol.2006.033787.
    1. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD) Eur Arch Psychiatry Clin Neurosci. 2006;256:i26–i31. doi: 10.1007/s00406-006-1004-4.
    1. Wagner ML, Walters AS, Fisher BC. Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome. Sleep. 2004;27:1499–1504.
    1. Surman CBH, Thomas RJ, Aleardi M, Pagano C, Biederman J. Adults with ADHD and sleep complaints: a pilot study identifying sleep-disordered breathing using polysomnography and sleep quality assessment. J Atten Disord. 2006;9:550–555. doi: 10.1177/1087054705282121.
    1. Naseem S, Chaudhary B, Collop N. Attention deficit hyperactivity disorder in adults and obstructive sleep apnea. Chest. 2001;119:294–296. doi: 10.1378/chest.119.1.294.
    1. Schredl M, Alm B, Sobanski E. Sleep quality in adult patients with attention deficit hyperactivity disorder (ADHD) Eur Arch Psychiatry Clin Neurosci. 2007;257:164–168. doi: 10.1007/s00406-006-0703-1.
    1. Kooij JJ, Middelkoop HA, van Gils K, Buitelaar JK. The effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study. J Clin Psychiatry. 2001;62:952–956.
    1. Philipsen A, Feige B, Hesslinger B, Ebert D, Carl C, Hornyak M, Lieb K, Voderholzer U, Riemann D. Sleep in adults with attention-deficit/hyperactivity disorder: a controlled polysomnographic study including spectral analysis of the sleep EEG. Sleep. 2005;28:877–884.
    1. Sobanski E, Schredl M, Kettler N, Alm B. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep. 2007;31:375–381.
    1. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry. 1996;35:599–605. doi: 10.1097/00004583-199605000-00014.
    1. Picchietti DL, Underwood DJ, Farris WA, Walters AS, Shah MM, Dahl RE, Trubnick LJ, Bertocci MA, Wagner M, Hening WA. Further studies on periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. Mov Disord. 1999;14:1000–1007. doi: 10.1002/1531-8257(199911)14:6<1000::AID-MDS1014>;2-P.
    1. Crabtree VM, Ivanenko A, O'Brien LM, Gozal D. Periodic limb movement disorder of sleep in children. J Sleep Res. 2003;12:73–81. doi: 10.1046/j.1365-2869.2003.00332.x.
    1. Chervin RD, Archbold KH, Dillon JE, Pituch KJ, Panahi P, Dahl RE, Guilleminault C. Associations between symptoms of inattention, hyperactivity, restless legs, and periodic leg movements. Sleep. 2002;25:213–218.
    1. Chervin RD, Dillon JE, Bassetti C, Ganoczy DA, Pituch KJ. Symptoms of sleep disorders, inattention, and hyperactivity in children. Sleep. 1997;20:1185–1192.
    1. Cohen-Zion M, Ancoli-Israel S. Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev. 2004;8:379–402. doi: 10.1016/j.smrv.2004.06.002.
    1. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S–49S.
    1. Cascade E, Kalali AH, Weisler RH. Short-acting versus Long-acting Medications for the Treatment of ADHD. Psychiatry (Edgemont) 2008;5:24–27.
    1. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434–443.
    1. Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K, Doyle R, Parekh A, Kagan J, Bearman SK. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775–782. doi: 10.1001/archpsyc.58.8.775.
    1. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ, on behalf of the SLI381.303 Study Group Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625–639.
    1. Stein D, Pat-Horenczyk R, Blank S, Dagan Y, Barak Y, Gumpel TP. Sleep disturbances in adolescents with symptoms of attention-deficit/hyperactivity disorder. J Learn Disabil. 2002;35:268–275. doi: 10.1177/002221940203500308.
    1. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65:27–37.
    1. Pearl PL. Sleep problems, stimulants, and ADHD: true, true, unrelated? Sleep Med. 2003;4:271–272. doi: 10.1016/S1389-9457(03)00070-4.
    1. Boonstra AM, Kooij JJ, Oosterlaan J, Sergeant JA, Buitelaar JK, Van Someren EJ. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep. 2007;30:433–442.
    1. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2008;12:308–315. doi: 10.1177/1087054708314844.
    1. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29:1573–1585.
    1. Pennick M. Hydrolytic conversion of lisdexamfetamine dimesylate to the active moiety, d-amphetamine. Poster presented at: Society of Biological Psychiatry's 64th Annual Scientific Convention and Meeting; May 14–16, 2009; Vancouver, British Columbia, Canada
    1. Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at: the 160th Annual Meeting of the American Psychiatric Association; May 19–24, 2007; San Diego, CA. Poster NR 740
    1. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450–463. doi: 10.1016/S0149-2918(07)80083-X.
    1. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970–976. doi: 10.1016/j.biopsych.2007.04.015.
    1. Wigal SB, Kollins SH, Childress AC, Squires L, 311 Study Group A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
    1. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J, on behalf of the 303 Study Group Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364–1373. doi: 10.4088/JCP.1108e31.
    1. Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. ADHD-RS Initial Evaluation
    1. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:187–201. doi: 10.1016/j.psc.2003.12.003.
    1. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112–120. doi: 10.1016/S0006-3223(02)01671-2.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa